Increased serum CEA levels have been demonstrated to be associated with a range of unfavourable clinical outcomes under nonmalignant conditions, as well as in malignant tumours, due to its overexpression in adenocarcinomas. The gene discussed is CEACAM5; the disease is adenocarcinoma.